TENAYA THERAPEUTICS INC (TNYA) Stock Price & Overview

NASDAQ:TNYA • US87990A1060

Current stock price

0.7512 USD
-0.05 (-6.53%)
At close:
0.75 USD
0 (-0.16%)
Pre-Market:

The current stock price of TNYA is 0.7512 USD. Today TNYA is down by -6.53%. In the past month the price increased by 21.3%. In the past year, price increased by 18%.

TNYA Key Statistics

52-Week Range0.36 - 2.35
Current TNYA stock price positioned within its 52-week range.
1-Month Range0.5316 - 1.035
Current TNYA stock price positioned within its 1-month range.
Market Cap
163.01M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.62
Dividend Yield
N/A

TNYA Stock Performance

Today
-6.53%
1 Week
-11.87%
1 Month
+21.30%
3 Months
+7.24%
Longer-term
6 Months -46.72%
1 Year +18.00%
2 Years -85.64%
3 Years -73.64%
5 Years N/A
10 Years N/A

TNYA Stock Chart

TENAYA THERAPEUTICS INC / TNYA Daily stock chart

TNYA Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to TNYA. When comparing the yearly performance of all stocks, TNYA is one of the better performing stocks in the market, outperforming 78.44% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

TNYA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to TNYA. No worries on liquidiy or solvency for TNYA as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TNYA Earnings

Next Earnings DateMay 1, 2026
Last Earnings DateMar 11, 2026
PeriodQ4 / 2025
EPS Reported-$0.12
Revenue Reported
EPS Surprise 2.97%
Revenue Surprise %

TNYA Forecast & Estimates

14 analysts have analysed TNYA and the average price target is 9.18 USD. This implies a price increase of 1122.04% is expected in the next year compared to the current price of 0.7512.


Analysts
Analysts84.29
Price Target9.18 (1122.04%)
EPS Next Y24.05%
Revenue Next YearN/A

TNYA Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

TNYA Financial Highlights

Over the last trailing twelve months TNYA reported a non-GAAP Earnings per Share(EPS) of -0.62. The EPS increased by 53.03% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-90.60M
Industry RankSector Rank
PM (TTM) N/A
ROA -61.66%
ROE -73.5%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%57.14%
Sales Q2Q%N/A
EPS 1Y (TTM)53.03%
Revenue 1Y (TTM)N/A

TNYA Ownership

Ownership
Inst Owners50.54%
Shares217.00M
Float215.37M
Ins Owners0.53%
Short Float %11.1%
Short Ratio4.95

About TNYA

Company Profile

TNYA logo image Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. The company is headquartered in South San Francisco, California and currently employs 70 full-time employees. The company went IPO on 2021-07-30. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene.

Company Info

IPO: 2021-07-30

TENAYA THERAPEUTICS INC

171 Oyster Point Blvd., Suite 500

South San Francisco CALIFORNIA US

CEO: Faraz Ali

Employees: 70

TNYA Company Website

TNYA Investor Relations

Phone: 14158652066

TENAYA THERAPEUTICS INC / TNYA FAQ

Can you describe the business of TENAYA THERAPEUTICS INC?

Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. The company is headquartered in South San Francisco, California and currently employs 70 full-time employees. The company went IPO on 2021-07-30. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene.


Can you provide the latest stock price for TENAYA THERAPEUTICS INC?

The current stock price of TNYA is 0.7512 USD. The price decreased by -6.53% in the last trading session.


Does TENAYA THERAPEUTICS INC pay dividends?

TNYA does not pay a dividend.


What is the ChartMill rating of TENAYA THERAPEUTICS INC stock?

TNYA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Which stock exchange lists TNYA stock?

TNYA stock is listed on the Nasdaq exchange.


Can you provide the upcoming earnings date for TENAYA THERAPEUTICS INC?

TENAYA THERAPEUTICS INC (TNYA) will report earnings on 2026-05-01.


What is the Short Interest ratio of TENAYA THERAPEUTICS INC (TNYA) stock?

The outstanding short interest for TENAYA THERAPEUTICS INC (TNYA) is 11.1% of its float.